(Q38937455)

7 September 2017

1 reference

title

The interplay between cell signalling and the mevalonate pathway in cancer (English)

1 reference

7 September 2017

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27562463%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Joseph Longo

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27562463%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Linda Z Penn

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27562463%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

author name string

Peter J Mullen

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27562463%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Michael C Archer

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27562463%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

language of work or name

English

0 references

publication date

26 August 2016

1 reference

7 September 2017

Nature Reviews Cancer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27562463%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27562463%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27562463%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

page(s)

718-731

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27562463%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrc.2016.76

13 June 2020

exact match

0 references

cites work

Metabolic pathways promoting cancer cell survival and growth

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Functional genomics reveal that the serine synthesis pathway is essential in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Acetate dependence of tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Acetate is a bioenergetic substrate for human glioblastoma and brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Recurring mutations found by sequencing an acute myeloid leukemia genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

An integrated genomic analysis of human glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Rare insights into cancer biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Familial hypercholesterolemia: identification of a defect in the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity associated with overproduction of cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Targeting tumor cell metabolism with statins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Acetyl coenzyme A: a central metabolite and second messenger

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Controlling cholesterol synthesis beyond 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Identification and characterization of essential genes in the human genome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Gene essentiality and synthetic lethality in haploid human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Exploiting the mevalonate pathway to distinguish statin-sensitive multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Identifying molecular features that distinguish fluvastatin-sensitive breast tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Dysregulation of the mevalonate pathway promotes transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Mevalonate promotes the growth of tumors derived from human cancer cells in vivo and stimulates proliferation in vitro with enhanced cyclin-dependent kinase-2 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

The Biological Synthesis of Cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

The Low-Density Lipoprotein Pathway and its Relation to Atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

The challenge of lipid rafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Lipid rafts as major platforms for signaling regulation in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Limiting Cholesterol Biosynthetic Flux Spontaneously Engages Type I IFN Signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Cholesterol masks membrane glycosphingolipid tumor-associated antigens to reduce their immunodetection in human cancer biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Targeting steroid hormone receptor pathways in the treatment of hormone dependent cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Targeting liver X receptors in cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Enzymes of the mevalonate pathway of isoprenoid biosynthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Mevalonate metabolism in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

T lymphocyte regulation by mevalonate metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

The p21 ras C-terminus is required for transformation and membrane association

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Derivatives of activated H-ras lacking C-terminal lipid modifications retain transforming ability if targeted to the correct subcellular location

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Posttranslational modification of the Ha-ras oncogene protein: evidence for a third class of protein carboxyl methyltransferases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Protein prenyltransferases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Immediate utility of two approved agents to target both the metabolic mevalonate pathway and its restorative feedback loop.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Determinants of sensitivity to lovastatin-induced apoptosis in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Mechanism of lovastatin-induced apoptosis in intestinal epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Lovastatin-induced up-regulation of the BH3-only protein, Bim, and cell death in glioblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Lovastatin-induced apoptosis in human melanoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Mevastatin can increase toxicity in primary AMLs exposed to standard therapeutic agents, but statin efficacy is not simply associated with ras hotspot mutations or overexpression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Protein lipid modifications--More than just a greasy ballast

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Targeting protein prenylation for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Drugging the undruggable RAS: Mission possible?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Anti-cancer therapy: targeting the mevalonate pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Geranylgeranyl diphosphate synthase: an emerging therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Farnesyltransferase inhibitors: where are we now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

The biological role of dolichol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Mevalonic acid is limiting for N-linked glycosylation and translocation of the insulin-like growth factor-1 receptor to the cell surface. Evidence for a new link between 3-hydroxy-3-methylglutaryl-coenzyme a reductase and cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Glycosylation in cancer: mechanisms and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Glucose-Mediated N-glycosylation of SCAP Is Essential for SREBP-1 Activation and Tumor Growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Biochemical, physiological and medical aspects of ubiquinone function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Mitochondrial genome acquisition restores respiratory function and tumorigenic potential of cancer cells without mitochondrial DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

SREBP-2, a second basic-helix-loop-helix-leucine zipper protein that stimulates transcription by binding to a sterol regulatory element

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

SREBP-1, a basic-helix-loop-helix-leucine zipper protein that controls transcription of the low density lipoprotein receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Differential expression of exons 1a and 1c in mRNAs for sterol regulatory element binding protein-1 in human and mouse organs and cultured cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Genome-wide analysis of SREBP-1 binding in mouse liver chromatin reveals a preference for promoter proximal binding to a new motif.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Genome-wide localization of SREBP-2 in hepatic chromatin predicts a role in autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

PI3K and cancer: lessons, challenges and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Platelet-derived growth factor stimulates membrane lipid synthesis through activation of phosphatidylinositol 3-kinase and sterol regulatory element-binding proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Vascular endothelial growth factor activation of sterol regulatory element binding protein: a potential role in angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Akt acutely activates the cholesterogenic transcription factor SREBP-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Diabetes and insulin in regulation of brain cholesterol metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

SREBPs: metabolic integrators in physiology and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Oncogenic PI3K and K-Ras stimulate de novo lipid synthesis through mTORC1 and SREBP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Control of lipid metabolism by phosphorylation-dependent degradation of the SREBP family of transcription factors by SCF(Fbw7).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Insulin enhances the biogenesis of nuclear sterol regulatory element-binding protein (SREBP)-1c by posttranscriptional down-regulation of Insig-2A and its dissociation from SREBP cleavage-activating protein (SCAP).SREBP-1c complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Distinct roles of insulin and liver X receptor in the induction and cleavage of sterol regulatory element-binding protein-1c

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Involvement of Akt in ER-to-Golgi transport of SCAP/SREBP: a link between a key cell proliferative pathway and membrane synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Insulin enhances post-translational processing of nascent SREBP-1c by promoting its phosphorylation and association with COPII vesicles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Positive feedback loop between PI3K-Akt-mTORC1 signaling and the lipogenic pathway boosts Akt signaling: induction of the lipogenic pathway by a melanoma antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

The biology of cancer: metabolic reprogramming fuels cell growth and proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Epidermal growth factor stimulates 3-hydroxy-3-methylglutaryl-coenzyme A reductase expression via the ErbB-2 pathway in human breast adenocarcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Making new contacts: the mTOR network in metabolism and signalling crosstalk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

4E-BP1 phosphorylation is mediated by the FRAP-p70s6k pathway and is independent of mitogen-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Activation of a metabolic gene regulatory network downstream of mTOR complex 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

The mammalian target of rapamycin regulates cholesterol biosynthetic gene expression and exhibits a rapamycin-resistant transcriptional profile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Development of ATP-competitive mTOR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Lipin-1 regulates autophagy clearance and intersects with statin drug effects in skeletal muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Expanding roles for SREBP in metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Sterol regulatory element binding protein-dependent regulation of lipid synthesis supports cell survival and tumor growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

LKB1 and AMPK and the cancer-metabolism link - ten years after

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

3-Hydroxy-3-methylglutaryl coenzyme A reductase: regulation of enzymatic activity by phosphorylation and dephosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Replacement of serine-871 of hamster 3-hydroxy-3-methylglutaryl-CoA reductase prevents phosphorylation by AMP-activated kinase and blocks inhibition of sterol synthesis induced by ATP depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

LKB1, a novel serine/threonine protein kinase and potential tumour suppressor, is phosphorylated by cAMP-dependent protein kinase (PKA) and prenylated in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Investigation of LKB1 Ser431 phosphorylation and Cys433 farnesylation using mouse knockin analysis reveals an unexpected role of prenylation in regulating AMPK activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

21 January 2018

Surfing the p53 network

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

ROS-mediated p53 induction of Lpin1 regulates fatty acid oxidation in response to nutritional stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Integrated genomic analyses of ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

The Molecular Taxonomy of Primary Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Comprehensive genomic characterization of squamous cell lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Rb Regulates DNA damage response and cellular senescence through E2F-dependent suppression of N-ras isoprenylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

MYC on the path to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Myc and its interactors take shape.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Reflecting on 25 years with MYC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Srebp-1 Interacts with c-Myc to Enhance Somatic Cell Reprogramming.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

An integrated encyclopedia of DNA elements in the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

BioID identifies novel c-MYC interacting partners in cultured cells and xenograft tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Reduced expression of MYC increases longevity and enhances healthspan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Metabolic control of YAP and TAZ by the mevalonate pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

YAP/TAZ at the Roots of Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

The emerging roles of YAP and TAZ in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Geranylgeranylation signals to the Hippo pathway for breast cancer cell proliferation and migration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

The LATS2 tumor suppressor inhibits SREBP and suppresses hepatic cholesterol accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Cholesterol and its derivatives in Sonic Hedgehog signaling and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Multiple roles for lipids in the Hedgehog signalling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Oxysterols stimulate Sonic hedgehog signal transduction and proliferation of medulloblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Activation of androgen receptor, lipogenesis, and oxidative stress converged by SREBP-1 is responsible for regulating growth and progression of prostate cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Regulation of the mevalonate pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Use of analgesics and nonsteroidal anti-inflammatory drugs, genetic predisposition, and bladder cancer risk in Spain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Statin use and reduced cancer-related mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Statin use and risk of prostate cancer and high-grade prostate cancer: results from the REDUCE study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Statins and cancer: A systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Comparative safety of cardiovascular medication use and breast cancer outcomes among women with early stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

P-glycoprotein has differential effects on the disposition of statin acid and lactone forms in mdr1a/b knockout and wild-type mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Statins: protectors or pretenders in prostate cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Lovastatin induces a pronounced differentiation response in acute myeloid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Coenzyme Q(10) and statin myalgia: what is the evidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Evidence-based management of statin myopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Chemoembolization combined with pravastatin improves survival in patients with hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

A phase II clinical trial does not show that high dose simvastatin has beneficial effect on markers of bone turnover in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Statins and cancer prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

A transcriptional signature and common gene networks link cancer with lipid metabolism and diverse human diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Genome-wide RNAi analysis reveals that simultaneous inhibition of specific mevalonate pathway genes potentiates tumor cell death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Synergistic effect of combined treatment with gamma-tocotrienol and statin on human malignant mesothelioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

A key regulator of cholesterol homoeostasis, SREBP-2, can be targeted in prostate cancer cells with natural products.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

A small molecule that blocks fat synthesis by inhibiting the activation of SREBP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Fatostatin displays high antitumor activity in prostate cancer by blocking SREBP-regulated metabolic pathways and androgen receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

A century of cholesterol and coronaries: from plaques to genes to statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Inhibition of SREBP by a Small Molecule, Betulin, Improves Hyperlipidemia and Insulin Resistance and Reduces Atherosclerotic Plaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Nelfinavir induces liposarcoma apoptosis through inhibition of regulated intramembrane proteolysis of SREBP-1 and ATF6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

A phase I trial of the HIV protease inhibitor nelfinavir with concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small cell lung cancer: a report of toxicities and clinical response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

The plasma membrane as a capacitor for energy and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Protein Geranylgeranyltransferase Type 1 as a Target in Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Essential role for oxidative phosphorylation in cancer progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

The functions and regulation of the PTEN tumour suppressor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Modulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity with cAMP and wth protein fractions of rat liver cytosol

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Reduced risk of breast cancer recurrence in patients using ACE inhibitors, ARBs, and/or statins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.76

Cholesterol accumulation in prostate cancer: a classic observation from a modern perspective.

31 March 2020

1 reference

12 December 2020

Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin.

1 reference

12 December 2020

Mevalonic acid induces DNA synthesis in chronic lymphocytic leukemia cells.

1 reference

12 December 2020

Sequence dependence of protein isoprenylation

1 reference

12 December 2020

Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study

1 reference

12 December 2020

Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations

1 reference

12 December 2020

Regulation of HMG-CoA reductase: identification of the site phosphorylated by the AMP-activated protein kinase in vitro and in intact rat liver

1 reference

12 December 2020

Transcriptional activities of nuclear SREBP-1a, -1c, and -2 to different target promoters of lipogenic and cholesterogenic genes

1 reference

12 December 2020

Regulation of sterol regulatory-element binding protein 1 gene expression in liver: role of insulin and protein kinase B/cAkt

1 reference

12 December 2020

In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients

1 reference

12 December 2020

Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin

1 reference

12 December 2020

Low-density lipoprotein (LDL) receptor activity in human acute myelogenous leukemia cells

1 reference

12 December 2020

Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach

1 reference

12 December 2020

Simvastatin and lovastatin inhibit breast cell invasion induced by H-Ras

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRC.2016.76

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27562463%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

13 June 2020

1052932418

0 references

Fatcat ID

release_e3gew3scavcidjv72vxm2c3jge

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/e3gew3scavcidjv72vxm2c3jge

24 November 2022

mapped directly with Wikidata item

1 reference